Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Chemicals signs distribution agreement with TCI
The deal is expected to provide Spectrum with access to line of organics for biochemical, R&D, medicinal chemistry and general laboratory use and enhances the Spectrum’s chemical offering
The deal is expected to provide Spectrum with access to line of organics for biochemical, R&D, medicinal chemistry and general laboratory use and enhances the Spectrum’s chemical offering
As per the agreement, Conformetrix’s technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification. The technology will also be used to
As per the transaction, entire share and equity interest of Eisai Machinery is transferred to the Bosch Group. Eisai’s machinery business is specialized in the manufacture, sales and
The ADX71441 compound, analyzed in female guinea pigs with bladder overactivity, induced an increase in inter contraction interval, a validated measure of bladder muscle control, in the first
The products achieved the target pharmacokinetic, pharmacodynamic and toleration profiles in a Phase I trial and BIOD-123 is expected to advance to Phase II in the third calendar
QGC001 is the first of a new class of drugs that can to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.
The product, a generic version of Novartis’ Lescol capsule, is indicated for the treatment of both familial and nonfamilial hypercholesterolemia, mixed dyslipidemia and also for the secondary prevention
CLEAR-108 is a 300-patient randomized phase 3 trial comparing Arikace 560mg, delivered once daily via PARI Pharma’s eFlow nebulizer system to Tobi (inhaled tobramycin solution). The eFlow nebulizer
Omontys is a once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the US. The Omontys-specific billing code, Q2047, which will become effective on
The FDA-approved Adcetris is an Antibody Drug Conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE),